Rachel Haurwitz, Caribou Biosciences CEO
Caribou says partial HLA matching will improve durability of response to cell therapy
CHICAGO — Caribou’s off-the-shelf cell therapy appears poised to break free from the rapid relapses that have plagued other off-the-shelf cell therapies, according to a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.